{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination is proposed to trigger type I interferon signaling and increase antigen processing/presentation in the tumor.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        },
        {
          "quote": "2. Interferon-associated antigen processing and presentation pathways increase.",
          "line_ref": "L43"
        }
      ],
      "caveat": "This is presented as a proposed mechanistic chain, and the report notes that some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C02",
      "claim": "Intratumoral mRNA vaccination broadened tumor antigen display in immunopeptidomics (62.3% versus 37.3% of tumor proteins represented).",
      "strength": "strong",
      "evidence": [
        {
          "quote": "| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |",
          "line_ref": "L28"
        },
        {
          "quote": "3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        }
      ],
      "caveat": "The report cautions that mouse model effects may not map one-to-one to all human tumors, so the magnitude of peptide-display changes may differ across settings."
    },
    {
      "claim_id": "C03",
      "claim": "Intratumoral mRNA vaccination expanded the fraction of proteins represented in the MHC-I peptidome (40.6% versus 20.6%).",
      "strength": "strong",
      "evidence": [
        {
          "quote": "| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |",
          "line_ref": "L29"
        },
        {
          "quote": "3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        }
      ],
      "caveat": "These measurements are drawn from preclinical tumor-model experiments, and the report notes that effects observed in mice may not translate directly across all human tumors."
    },
    {
      "claim_id": "C04",
      "claim": "mRNA vaccination increased PD-L1 expression in tumor tissue (2.4x), supporting a rationale for combining vaccination with checkpoint blockade.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "| PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |",
          "line_ref": "L32"
        },
        {
          "quote": "4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.",
          "line_ref": "L45"
        }
      ],
      "caveat": "An increase in PD-L1 does not by itself prove improved clinical benefit, and the report emphasizes that prospective randomized studies are required before clinical protocol changes are justified."
    },
    {
      "claim_id": "C05",
      "claim": "In a retrospective metastatic patient cohort receiving ICI therapy, prior SARS-CoV-2 mRNA vaccination was associated with improved survival (p=0.01).",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.",
          "line_ref": "L15"
        },
        {
          "quote": "| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |",
          "line_ref": "L30"
        },
        {
          "quote": "- The human analysis is retrospective and non-randomized; residual confounding is likely.",
          "line_ref": "L49"
        }
      ],
      "caveat": "Because the analysis is retrospective with varied vaccination timing and heterogeneous tumor types/treatment histories, the observed association cannot be interpreted as causal."
    },
    {
      "claim_id": "C06",
      "claim": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the sensitization benefit attributed to intratumoral mRNA vaccination.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        },
        {
          "quote": "1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "This perturbation result is reported for the preclinical system, and the report notes that mouse model effects may not map one-to-one to all human tumors."
    }
  ]
}
